Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 10:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 625 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Esophageal studies Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

The EndoGastric Solutions TEMPO Trial

NCT01647958
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
EsophyX System with SerosaFuse fasteners, PPI
Device · Drug
Lead sponsor
EndoGastric Solutions
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 11, 2026, 10:05 AM EDT
Completed Phase 3 Interventional

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

NCT04543617
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Tiragolumab, Atezolizumab, Tiragolumab Matching Placebo, Atezolizumab Matching Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Fort Myers, Florida • Wichita, Kansas • Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 11, 2026, 10:05 AM EDT
Not yet recruiting Phase 2 Interventional

PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC

NCT07836049
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Toripalimab, Carboplatin + Paclitaxel
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 11, 2026, 10:05 AM EDT
Withdrawn Phase 3 Interventional

Carvedilol vs Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding

NCT02066649
View directory record Official record
Conditions
Portal Hypertension Related to Cirrhosis
Interventions
Carvedilol, Variceal band ligation
Drug · Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 11, 2026, 10:05 AM EDT
Not listed Not applicable Interventional

Non-endoscopic Esophageal Sampling to Detect Barrett's Esophagus and Esophageal Cancer in Veterans

NCT05210049
View directory record Official record
Conditions
Barrett Esophagus, GERD, Obesity, Esophageal Cancer
Interventions
Esocheck/Esoguard
Diagnostic Test
Lead sponsor
Louis Stokes VA Medical Center
Federal
Eligibility
40 Years to 85 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 11, 2026, 10:05 AM EDT
Completed Not applicable Interventional

EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures

NCT01681225
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Esophageal-pressure guided mechanical ventilation, High PEEP mechanical ventilation
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
16 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
La Jolla, California • Stanford, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 11, 2026, 10:05 AM EDT
Completed Not applicable Interventional

Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium

NCT01293448
View directory record Official record
Conditions
Barrett's Esophagus, Esophageal Cancer
Interventions
Cryoballoon Ablation
Device
Lead sponsor
Pentax Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Rochester, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 11, 2026, 10:05 AM EDT
Recruiting Not applicable Interventional

Serial MRI Scans During Radiation Therapy

NCT04188535
View directory record Official record
Conditions
Glioblastoma, Esophageal Cancer, Radiotherapy, Magnetic Resonance Imaging, MRI, Prostate Cancer, Vulvar Cancer, Pediatric Glioblastoma Multiforme, Sarcoma
Interventions
MRI IMAGING
Diagnostic Test
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 11, 2026, 10:05 AM EDT
Completed Phase 2 Interventional Results available

IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma

NCT03795610
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Cancer Stage IV, Head and Neck Cancer Stage III, HPV-Related Carcinoma, HPV-Related Malignancy, HPV-Related Squamous Cell Carcinoma
Interventions
IPI-549
Drug
Lead sponsor
Assuntina G. Sacco, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 11, 2026, 10:05 AM EDT
Completed Not applicable Interventional Results available

Esophageal Manometry During Recovery From Anesthesia: Pilot Study

NCT02661386
View directory record Official record
Conditions
Motility Function
Interventions
Motility Procedure
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 11, 2026, 10:05 AM EDT
Completed Phase 2 Interventional Results available

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

NCT04704154
View directory record Official record
Conditions
Solid Tumors
Interventions
Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 11, 2026, 10:05 AM EDT
Completed Phase 1 Interventional

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

NCT00002854
View directory record Official record
Conditions
Cancer
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 11, 2026, 10:05 AM EDT
Terminated Not applicable Interventional Results available

Spray Cryotherapy for Esophageal Cancer (ICE-CANCER)

NCT01868139
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Liquid nitrogen spray cryotherapy with the truFreeze device
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 11, 2026, 10:05 AM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 11, 2026, 10:05 AM EDT
Completed Not applicable Interventional Results available

An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter

NCT01058070
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Torax Medical, Inc. LINX Reflux Management System
Device
Lead sponsor
Torax Medical Incorporated
Industry
Eligibility
18 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Los Angeles, California • Orange, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 11, 2026, 10:05 AM EDT
Completed No phase listed Observational

Evaluation of Performance Characteristics of Capsule Endoscopy With PillCam UGI Capsule Compared to Standard Endoscopy

NCT03167970
View directory record Official record
Conditions
Barrett Esophagus
Interventions
Pill cam, EGD
Device · Other
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
18 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 11, 2026, 10:05 AM EDT
Terminated No phase listed Observational

Study of 124I-NM404 in Advanced Solid Malignancies

NCT01662284
View directory record Official record
Conditions
Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer
Interventions
124I-NM404
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 11, 2026, 10:05 AM EDT
Completed Phase 2 Interventional Results available

Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy

NCT01129206
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus, Stage IV Esophageal Cancer
Interventions
pralatrexate, docetaxel, fludeoxyglucose F 18, positron emission tomography
Drug · Radiation · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 11, 2026, 10:05 AM EDT
Completed Phase 2 Interventional

Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening

NCT05396781
View directory record Official record
Conditions
Suspected or Known Squamous Cell Neoplasia, Prior History of Squamous Cell Dysplasia and /or Neoplasia
Interventions
Proflavine, Mobile, Augmented High Resolution Microendoscope
Drug · Device
Lead sponsor
Anandasabapathy, Sharmila, M.D.
Individual
Eligibility
18 Years to 64 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 11, 2026, 10:05 AM EDT
Active, not recruiting Phase 1 Interventional

Cryotherapy for Locally Advanced Esophageal Cancer

NCT04248582
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Cryotherapy
Device
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 11, 2026, 10:05 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

NCT04772989
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
Interventions
AB308, Zimberelimab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Los Angeles, California • Jacksonville, Florida • Goshen, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 11, 2026, 10:05 AM EDT
Terminated Phase 1 Interventional

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

NCT02283359
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Selinexor, Irinotecan
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 11, 2026, 10:05 AM EDT
Completed Not applicable Interventional Results available

Effect of Goal-directed Crystalloid Versus Colloid Administration on Major Postoperative Morbidity

NCT01195883
View directory record Official record
Conditions
Postoperative Complications
Interventions
Crystalloid, Colloid
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
1,102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Cleveland, Ohio • Mayfield Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 11, 2026, 10:05 AM EDT
Recruiting Phase 2 Interventional

Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

NCT05384496
View directory record Official record
Conditions
Mucosal Melanoma
Interventions
Nivolumab and/or Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), axitinib
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 11, 2026, 10:05 AM EDT